GAITHERSBURG, Md., April 27, 2016 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2016 financial and operating results after the close of U.S. financial markets on Wednesday, May 4, 2016.
Management will host a conference call to discuss the quarterly financial results and provide an update on corporate activities.
Conference call details are as follows:
| Date: | Wednesday, May 4, 2016 |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Passcode: | 95870834 |
| Via web: | www.novavax.com, “Investors”/ “Events” |
Conference call replay:
| Dates: | Starting at 7:00 p.m. ET, May 4, 2016 until midnight May 11, 2016 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 95870834 |
| Via web: | www.novavax.com, “Investors”/ “Events” |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
CONTACT: Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations ir@novavax.com 240-268-2000
